Figure 4 | Scientific Reports

Figure 4

From: Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer

Figure 4

Treatment outcome according to changes in dNLR from baseline (BL) in D-group. (A) PFS (B) OS in patients of BL-low/28-low and BL-low/28-high groups. (C) PFS and (D) OS in patients with BL-high/28-low and BL-high/28-high groups. dNLR, derived neutrophil-to-lymphocyte ratio; D group, durvalumab group; PFS, progression-free survival; OS, overall survival; NA, not applicable; BL-low/28-low, patients with baseline dNLR ≤ 3 and dNLR28 ≤ 3; BL-low/28-high, patients with baseline dNLR ≤ 3 and dNLR28 > 3; BL-high/28-low, patients with baseline dNLR > 3 and dNLR28 ≤ 3; BL-high/28-low, patients with baseline dNLR > 3 and dNLR28 ≤ 3.

Back to article page